Press release
Two University of Dundee initiatives are to benefit from millions of pounds of UK Government investment.
Press release
Two University of Dundee initiatives are to benefit from millions of pounds of UK Government investment.
News
A University of Dundee spinout has announced a multi-million pound deal to develop first-in-class therapeutics that restore the body's natural disease suppression processes.
Press release
The Biochemical Society have given their annual Industry and Academic Collaboration Award to Professor Gopal Sapkota, of the University of Dundee
Press release
Ground-breaking drug discovery work at the University of Dundee has been honoured at a national awards ceremony.
Press release
The University of Dundee is leading an international collaboration with the intention of developing the first vaccine for Strep A.
Press release
World-leading expertise from the University of Dundee’s Centre for Targeted Protein Degradation (CeTPD) will contribute to a new, global effort to tackle some of the most significant challenges posed by cancer.
Press release
Some of Scotland’s brightest business prospects are preparing for an exciting future after being crowned winners of a major Scottish competition.
Press release
University of Dundee spinout Amphista Therapeutics has been designated as one of the world’s most promising biotechnology companies.
Press release
The University of Dundee and Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents, will partner to commercialise technology developed at Dundee that enhances the understanding of undruggable diseases.
Press release
University of Dundee spinout Amphista Therapeutics will work with global biopharmaceutical companies as part of strategic collaborations potentially worth more than $2 billion.
News
Amphista Therapeutics, the spin out company from the lab of Professor Alessio Ciulli, was awarded the ‘Financing Deal of the Year’ award 2021 at the Scrip Awards last month. This was in recognition of their $53M Series B funding.